Home › Atherosclerosis › South Carolina
Atherosclerosis clinical trials in South Carolina
6 studies for Atherosclerosis are looking for participants at sites in South Carolina.
Cities in South Carolina
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Monroe Biomedical Research - Charleston, North Charleston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07783802Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
- M3 Wake Research - Charleston, Charleston
- Medical University of South Carolina, Charleston
- Walker Family Care, Little River
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07157774Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Accellacare Charleston, Mt. Pleasant
RecruitingPhase 3
Ages 45 to 99 · All sexes · Updated Sep 22, 2026 · NCT07037433Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
- Columbia Nephrology, Columbia
- CN Clinical Research LLC, Greenville
- Dialysis Clinic, Inc., Spartanburg
- and 1 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05485961A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
- Research Site, Charleston
- Research Site, Fort Mill
- Research Site, Mauldin
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT07000357Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
- Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston
- Wm. Jennings Bryan Dorn VA Medical Center, Columbia, SC, Columbia
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Dec 17, 2025 · NCT02915198From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.